Michael Barbella, Managing Editor12.17.22
'Tis the season for retrospection and anticipation, apparently.
With the end of 2022 fast approaching, MPO cybervisitors joined the magazine's Advisory Board members in reflecting upon the year's most memorable issues and events, and looking with hope (and a bit of uncertainty) to 2023. Members who provided input included Randy Clark, president of Health Solutions at Flex; Steve Maylish, chief commercial officer at at Fusion Biotec; Paul Orlando, Global Operations Business Development lead for OLYMPUS SURGICAL TECHNOLOGIES AMERICA; Dennis Rubenacker, senior partner at Noblitt & Rueland (on behalf of EAB member Brent Noblitt); and Dave Sheppard, CMAA, co-founder and managing director at MedWorld Advisors. Clark expects wearables to gain further market share next year, while Sheppard anticipates the continued melding of the digital and consumer health tech arenas.
Hints of future tidings of great (market) joy from Tandem Diabetes Care, Masimo, and Medtronic plc helped drive website traffic this past week. Tandem Diabetes began an agreement to acquire AMF Medical SA, the privately-held Swiss developer of the Sigi patch pump. Sigi is currently under development and not commercially available; it is designed to be an ergonomic, rechargeable patch pump that lowers the burden of diabetes through the use of pre-filled insulin cartridges and compatibility with automated insulin technology.
Also garnering pageviews was Masimo's limited market release of its Sepsis Index (Si) early warning indicator to help identify possible sepsis in patients being remotely monitored with Masimo’s Patient SafetyNet, and the start of Medtronic’s Expand URO U.S. clinical trial for its Hugo robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital.
Researchers from the University of Florida and National Yang Ming Chiao Tung University in Taiwan ranked high on the story popularity list, thanks to their development of a breakthrough hand-held biosensor that enables quick and accurate oral cancer detection. The group's biosensor consists of a sensor strip, similar to a glucose strip, and a circuit board (a hand-held terminal like a glucometer) for detection.
With the end of 2022 fast approaching, MPO cybervisitors joined the magazine's Advisory Board members in reflecting upon the year's most memorable issues and events, and looking with hope (and a bit of uncertainty) to 2023. Members who provided input included Randy Clark, president of Health Solutions at Flex; Steve Maylish, chief commercial officer at at Fusion Biotec; Paul Orlando, Global Operations Business Development lead for OLYMPUS SURGICAL TECHNOLOGIES AMERICA; Dennis Rubenacker, senior partner at Noblitt & Rueland (on behalf of EAB member Brent Noblitt); and Dave Sheppard, CMAA, co-founder and managing director at MedWorld Advisors. Clark expects wearables to gain further market share next year, while Sheppard anticipates the continued melding of the digital and consumer health tech arenas.
Hints of future tidings of great (market) joy from Tandem Diabetes Care, Masimo, and Medtronic plc helped drive website traffic this past week. Tandem Diabetes began an agreement to acquire AMF Medical SA, the privately-held Swiss developer of the Sigi patch pump. Sigi is currently under development and not commercially available; it is designed to be an ergonomic, rechargeable patch pump that lowers the burden of diabetes through the use of pre-filled insulin cartridges and compatibility with automated insulin technology.
Also garnering pageviews was Masimo's limited market release of its Sepsis Index (Si) early warning indicator to help identify possible sepsis in patients being remotely monitored with Masimo’s Patient SafetyNet, and the start of Medtronic’s Expand URO U.S. clinical trial for its Hugo robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital.
Researchers from the University of Florida and National Yang Ming Chiao Tung University in Taiwan ranked high on the story popularity list, thanks to their development of a breakthrough hand-held biosensor that enables quick and accurate oral cancer detection. The group's biosensor consists of a sensor strip, similar to a glucose strip, and a circuit board (a hand-held terminal like a glucometer) for detection.